CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open account
☰
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open account
✖

FTSE slips 0 6 as investors remain cautious ahead of a busy week for the markets

Article By: ,  Financial Analyst
January 9, 2011 3:52 PM

It has been an uncertain start to the second week of 2012 for the FTSE 100. London’s major index has swung in and out of positivity in a 75-point range, but slipped into negative territory as it heads for the close. Traders are forgiven for indecision though, given the raft of data, meetings, auctions and results due in the next four days.

In their first meeting of 2012, Chancellor Merkel and President Sarkozy announced today that the new budget rule book designed to instil further fiscal discipline will be complete by January 30, a month ahead of schedule. They will also look to accelerate capital contributions to the bailout fund in order to stem the debt crisis.

Of concern to the market though is their insistence that private investors (including banks and hedge funds) take losses on their Greek bonds to help reduce the Greek debt burden. Talks between Greek government officials and private bondholders are progressing but, according to a Reuters source, “were very difficult and likely to be unsuccessful”.  The euro is now trading at the lows of the day against the USD.

London risers and fallers
Following the release of clinical trial results, GlaxoSmithKline has announced it will file for regulatory approval for once-a-day inhaled lung drug Relovair. The stock is trading down 4.48% to 1430p and is amongst the biggest fallers on the FTSE 100. Whilst warranting selling commercially, the trial data suggests the drug is not superior to GSK’s existing respiratory drug, Advair.

In a welcome respite from news about their regulatory problems, Indian energy firm Essar Energy announced an expansion to its Vadinar Refinery. Phase 1 is near completion and the increase in output will commence in March 2012. Clearly the beleaguered company must do more; the shares traded down 4.6% to 163p.

Tomorrow
One of the barometers of the UK high street health will update the market on its Christmas sales. The Telegraph states that Marks & Spencer will post good figures and that its non-food sales might even be steady with last year.

StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. CFD and Forex Trading are leveraged products and your capital is at risk. They may not be suitable for everyone. Please ensure you fully understand the risks involved by reading our full risk warning.

City Index is a trading name of StoneX Financial Ltd. Head and Registered Office: 1st Floor, Moor House, 120 London Wall, London, EC2Y 5ET. StoneX Financial Ltd is a company registered in England and Wales, number: 05616586. Authorised and regulated by the Financial Conduct Authority. FCA Register Number: 446717.

City Index is a trademark of StoneX Financial Ltd.

The information on this website is not targeted at the general public of any particular country. It is not intended for distribution to residents in any country where such distribution or use would contravene any local law or regulatory requirement.

© City Index 2024